Management of asthma with Zafirlukast. Clinical experience and tolerability profile

Drugs

Volumn 52, Issue SUPPL. 6, 1996, Pages 36-46

  Spector, Sheldon L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE; BRONCHODILATING AGENT; CROMOGLYCATE DISODIUM; LEUKOTRIENE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; ZAFIRLUKAST;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BLOOD VESSEL PERMEABILITY; BRONCHODILATATION; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EXERCISE INDUCED ASTHMA; FORCED EXPIRATORY VOLUME; GASTRITIS; HEADACHE; HUMAN; INFLAMMATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; META ANALYSIS; MUCOCILIARY TRANSPORT; MUCUS SECRETION; ORAL DRUG ADMINISTRATION; PHARYNGITIS; REVIEW; RHINITIS;

EID: 0029955405     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199600526-00007     Document Type: Review

References (46)

1. Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol 1938; 94: 187-226
2. Kellaway CH, Trethewie RE. The liberation of a slow reacting smooth muscle stimulating substance of anaphylaxis. J Exp Physiol 1940; 30: 121-45
3. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220: 568-75
4. Henderson WRJ. Eicosanoids and lung inflammation. Am Rev Respir Dis 1987; 135: 1176-85
5. Executive Summary. Guidelines for the diagnosis and management of asthma. In: National Institutes of Health Expert Panel Report: publication no. 91-3042, 1991: Bethesda, Maryland: 1-136
6. Spector SL, Nicklas RA, editors. Practice parameters for the diagnosis and treatment of asthma. J Allergy Clin Immunol 1995; 96 Suppl.: 707-858
7. Drazen JM, Austen KF, Lewis RA, et al. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci USA 1980; 77: 4354-8
8. Rinkema LE, Bemis KG, Fleish JH. Production and antagonism of cutaneous vascular permeability in the guinea pig in response to histamine, leukotrienes, and A23187. J Pharmacol Exp Ther 1984; 230: 550-7
9. 4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982; 126: 449-51
10. Drazen JM. Inhalation challenge with sulfidopeptide leukotrienes in human subjects. Chest 1986; 89: 414-9
11. 4: biologic properties and regulation of biosynthesis. In: Piper PJ, editor. The leukotrienes: their biological significance. New York: Raven Press, 1986: 141-50
12. 4 on human neutrophils. Ann N Y Acad Sci 1988; 524: 187-95
13. 4 effects on in vitro ciliary beat frequency of human upper respiratory cilia. Eur Arch Otorhinolaryngol 1994; 251: 325-8
14. 4. Proc Natl Acad Sci USA 1983; 80: 1712-6
15. 4. Acta Physiol Scand 1980; 110: 331-3
16. Fabbri LM, Boschetto P, Zocca E, et al. Bronchoalveolar neutrophilia during late asthmatic reactions induced by toluene diisocyanate. Ann Rev Respir Dis 1987; 136 (1): 36-42
17. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Eng J Med 1991; 324: 1514-5
18. Buckner CK, Fedyna JS, Robertson JL, et al. An examination of the influence of the epithelium on contractile responses to peptidoleukotrienes and blockade by ICI 204,219 in isolated guinea-pig trachea and human intralobar airways. J Pharmacol Exp Ther 1989; 252: 77-85
19. Chanarin N, Johnston SL. Leukotrienes as a target in asthma therapy. Drugs 1994; 47: 12-24
20. 4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1990; 141: 988-92
21. 4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI-204,219. Clin Pharmacol Ther 1993; 54: 430-6
22. Schellenberg RR, Walker B. Platelet-dependent contraction of human bronchus by platelet-activating factor. J Allergy Clin Immunol 1983; 71: 154
23. 2 production in humans. J Appl Physiol 1991; 71: 1396-402
24. 4 receptor antagonist. ICI 204,219. Am Rev Respir Dis 1993; 147: 215-7
25. Taylor IK, O'Shaughnessy KM, Fuller RW, et al. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen induced bronchoconstriction and airways hyperreactivity in atopic subjects. Lancet 1991; 337: 690-4
26. Findlay SR, Barden JM, Easley CB, et al. Effect of the oral leukotriene antagonist, ICI-204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992; 89: 1040-5
27. Dahlen B, Zetterstrom O, Bjorck T, et al. The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J 1994; 7: 324-31
28. 4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase response of allergen-induced bronchoconstriction. Am Rev Respir Dis 1993; 147: 1431-5
29. Nathan RA, Glass M, Minkwitz MC. Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest 1994; 105: 483-8
30. Calhoun WJ, Lavins BJ, Glass M. Effect of 'Accolate' (zafirlukast) on bronchoalveolar lavage fluid (BAL) after segmental bronchoprovocation (SBP) in patients with mild to moderate asthma [abstract]. Am J Respir Crit Care Med 1995; 151: A42
31. 2)-induced bronchoconstriction in patients with asthma [abstract]. Am J Respir Crit Care Med 1995; 151: A41
32. Juniper EF, Kline PA, Vanzielehgem MA, et al. Effect of long-term treatment with an inhaled corticosteroid on airway hyperresponsiveness and clinical asthma in non-steroid dependent asthmatics. Am Rev Respir Dis 1990; 142: 832-6
33. 4-receptor antagonist, ICI 204,219, on cold-air-induced bronchoconstriction in patients with asthma [abstract]. J Allergy Clin Immunol 1994; 93: 295
34. Spector SL. Update on exercise-induced asthma. Ann Allergy 1993; 71: 571-7
35. 4 antagonist. Am Rev Respir Dis 1992; 145: 746-9
36. 4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993; 147: 1413-8
37. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337: 1062-3
38. Kemp JP, Glass M, Minkwitz MC. Onset of action of the leukotriene-receptor antagonist, zafirlukast (Accolate™), in patients with asthma [abstract]. J Allergy Clin Immunol 1995; 95: 351
39. Spector SL, Glass M, Minkwitz M, et al. The effect of six weeks of therapy with oral doses of ICI 204,219 in asthmatics [abstract]. Am Rev Respir Dis 1992; 145: A16
40. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 618-23
41. Howland WI, Segal A, Glass M, et al. 6-week therapy with the oral leukotriene-receptor antagonist, ICI 204,219 in the treatment of asthma [abstract]. J Allergy Clin Immunol 1994; 93: 259
42. Spector S, Miller CJ, Glass M. 13-week dose-response study with Accolate™ (zafirlukast) in patients with mild-to-moderate asthma [abstract]. Am J Resp Crit Care Med 1995; 151: A379
43. Lockey RF, Lavins BJ, Snader L. Effects of 13 weeks of treatment with ICI 204,219 (Accolate™) in patients with mild-to-moderate asthma [abstract]. J Allergy Clin Immunol 1995; 95: 350
44. Holgate ST, Anderson KD, Rodgers EM. Comparison of 'Accolate' (zafirlukast) with sodium cromoglycate in mild to moderate asthmatic patients [abstract]. Allergy 1995; 50: 319-20
45. Nathan RA, Glass M, Snader L. Effects of 13 weeks of treatment with ICI 204,219 ('Accolate') or cromolyn sodium ('Intal') in patients with mild to moderate asthma [abstract]. J Allergy Clin Immunol 1995; 95: 388
46. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994; 154: 1349-52